Browse evidence-based analysis of health-related claims and assertions
People with type 2 diabetes who are sedentary and obese take longer to recover their muscle energy levels after exercise compared to obese people without diabetes, as measured by how quickly their muscles use up ADP.
At the start of the study, people with HIV who had denser thigh muscles also had lower levels of certain inflammation markers, like TNF-alpha and IL-6.
The exercise program didn't change levels of inflammation markers in older people with HIV compared to those who didn't exercise.
Older people with HIV who did the exercise program for 16 weeks probably had much stronger legs (51.8% increase) compared to those who didn't (1.3% increase), and this difference was highly significant.
Older adults with HIV who exercised for 16 weeks likely had denser thigh muscles (5.2% increase) compared to the control group (0.3% decrease), which was statistically significant.
Older people with HIV who did aerobic and resistance exercise for 16 weeks probably had bigger thigh muscles (7.5% increase) compared to those who didn't (3.1% decrease), and this difference was statistically significant.
In obese people with low growth hormone taking tesamorelin, higher IGF-I levels are linked to better mitochondrial energy efficiency, measured by τPCr.
When only looking at the best-quality muscle energy recovery data, higher IGF-I still links to better recovery in obese people with low growth hormone.
Changes in IGF-I levels don't relate to how much phosphocreatine is used up during exercise or muscle strength in obese people with low growth hormone.
Taking tesamorelin for a year doesn't change blood sugar, insulin levels, or insulin resistance in obese people with low growth hormone.
Even when accounting for factors like age, weight, and insulin levels, higher IGF-I still links to better muscle energy recovery in obese people with low growth hormone.
In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.
When IGF-I levels go up in obese people with low growth hormone, their muscles recover energy faster after exercise, and this connection is statistically significant.
Taking tesamorelin for a year makes IGF-I levels rise much more in obese people with low growth hormone than taking a dummy pill, with a clear difference between the two groups.
The improvements in how the body uses insulin didn't relate to changes in fat stored in organs or specific body areas. This finding is from the abstract summary - full study details were not available
The exercise program didn't affect fat stored in organs like the liver or muscles in these women. This finding is from the abstract summary - full study details were not available
Regular exercise helped reduce fat around the hips and thighs in obese black South African women. This finding is from the abstract summary - full study details were not available
After exercising regularly for 12 weeks, the women's bodies became better at using insulin to manage blood sugar levels. This finding is from the abstract summary - full study details were not available
Doing regular exercise for 12 weeks helped improve heart and lung fitness in obese black South African women, as measured by their ability to use oxygen during exercise. This finding is from the abstract summary - full study details were not available
For HIV patients with belly fat on tesamorelin, losing belly fat was linked to better muscle density in their abdominal and rectus muscles.
HIV patients with belly fat who responded to tesamorelin had more lean muscle mass in all four trunk muscles, with increases between 0.64 and 1.08 cm² compared to placebo after 26 weeks.
HIV patients with belly fat who responded to tesamorelin had bigger rectus and psoas muscles (0.44 and 0.46 cm² larger) compared to placebo after 26 weeks.
HIV patients with belly fat who responded to tesamorelin saw better lean muscle quality in their abdominal and rectus muscles, with improvements of 1.39 and 1.78 units respectively compared to placebo after 26 weeks.
For HIV patients with belly fat who responded to tesamorelin, the drug was linked to better muscle density in four trunk muscles, with improvements between 1.56 and 4.86 units compared to placebo after 26 weeks.